Living Donors Online Message Board
Living Donation Discussion and News => Living Donation in the News => Topic started by: Clark on September 10, 2023, 06:10:25 PM
-
https://www.amjtransplant.org/article/S1600-6135(23)00457-4/fulltext (https://www.amjtransplant.org/article/S1600-6135(23)00457-4/fulltext)
CASE REPORT| VOLUME 23, ISSUE 9 (https://www.amjtransplant.org/issue/S1600-6135(23)X0013-6), P1451-1454, SEPTEMBER 2023
The first successful case of ABO-incompatible living-donor lobar lung transplantation following desensitization therapy
Daisuke Nakajima (https://www.amjtransplant.org/article/S1600-6135(23)00457-4/fulltext#)
Itsuki Yuasa (https://www.amjtransplant.org/article/S1600-6135(23)00457-4/fulltext#)
Hidenao Kayawake (https://www.amjtransplant.org/article/S1600-6135(23)00457-4/fulltext#)
Shiro Baba (https://www.amjtransplant.org/article/S1600-6135(23)00457-4/fulltext#)
Hidefumi Hiramatsu (https://www.amjtransplant.org/article/S1600-6135(23)00457-4/fulltext#)
Hiroshi Date (https://www.amjtransplant.org/article/S1600-6135(23)00457-4/fulltext#)
et al.
American Journal of Transplantation
Published:May 04, 2023
DOI:https://doi.org/10.1016/j.ajt.2023.04.031 (https://doi.org/10.1016/j.ajt.2023.04.031)
Abstract
ABO-incompatible (ABO-I) living-donor lobar lung transplantation (LDLLT) was successfully performed in a 14-year-old girl who suffered from bronchiolitis obliterans due to graft-versus-host disease following hematopoietic stem cell transplantation. In the ABO-I LDLLT procedure, the blood type O patient received a right lower lobe donated from her blood type B father and a left lower lobe donated from her blood type O mother. Desensitization therapy, using rituximab, immunosuppressants, and plasmapheresis, was implemented for 3 weeks prior to transplantation to reduce the production of anti-B antibodies in the recipient and prevent acute antibody-mediated rejection after ABO-I LDLLT.